國家衛生研究院 NHRI:Item 3990099045/10084
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856841      線上人數 : 935
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10084


    題名: Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
    作者: Chang Hsu, Y;Selvaraj Coumar, M;Wang, WC;Shiao, HY;Ke, YY;Lin, WH;Kuo, CC;Chang, CW;Kuo, FM;Chen, PY;Wang, SY;Li, AS;Chen, CH;Kuo, PC;Chen, CP;Wu, MH;Huang, CL;Yen, KJ;Chang, YI;Hsu, JT;Chen, CT;Yeh, TK;Song, JS;Shih, C;Hsieh, HP
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: The design and synthesis of a quinazoline-based, multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and other malignancies is reported. Based on the previously reported furanopyrimidine 3, quinazoline core containing lead 4 was synthesized and found to impart dual FLT3/AURKA inhibition (IC50 = 127/5 nM), as well as improved physicochemical properties. A detailed structure-activity relationship study of the lead 4 allowed FLT3 and AURKA inhibition to be finely tuned, resulting in AURKA selective (5 and 7; 100-fold selective over FLT3), FLT3 selective (13; 30-fold selective over AURKA) and dual FLT3/AURKA selective (BPR1K871; IC50 = 19/22 nM) agents. BPR1K871 showed potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells (EC50 ~ 5 nM). Moreover, kinase profiling and cell-line profiling revealed BPR1K871 to be a potential multi-kinase inhibitor. Functional studies using western blot and DNA content analysis in MV4-11 and HCT-116 cell lines revealed FLT3 and AURKA/B target modulation inside the cells. In vivo efficacy in AML xenograft models (MOLM-13 and MV4-11), as well as in solid tumor models (COLO205 and Mia-PaCa2), led to the selection of BPR1K871 as a preclinical development candidate for anti-cancer therapy. Further detailed studies could help to investigate the full potential of BPR1K871 as a multi-kinase inhibitor.
    日期: 2016-12
    關聯: Oncotarget. 2016 Dec;7(52):86239-86256.
    Link to: http://dx.doi.org/10.18632/oncotarget.13369
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000391422500047
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85007494556
    顯示於類別:[謝興邦] 期刊論文
    [石全(2014-2017)] 期刊論文
    [葉燈光] 期刊論文
    [陳炯東] 期刊論文
    [郭靜娟] 期刊論文
    [徐祖安] 期刊論文
    [王文傑] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB27863392.pdf4233KbAdobe PDF524檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋